CAMMA-1
Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 1
- Enrollment
- 170 patients (estimated)
- Sponsors
- Genentech
- Collaborators
- Hoffmann-La Roche
- Tags
- Bispecific Antibody, CD3, FCRH5
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1175
- NCT Identifier
- NCT04910568
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.